ELDN

Eledon Pharmaceuticals, Inc. [ELDN] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ELDN Stock Summary

Top ELDN Correlated Resources

ELDN

Top 10 Correlated ETFs

ELDN

Top 10 Correlated Stocks

ELDN

In the News

ELDN Financial details

Company Rating
-
Market Cap
40.89M
Income
-39.99M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
20
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-0.64
Forward P/E
-
PEG
0.09
P/S
-
P/B
0.62
P/C
-
P/FCF
-1.15
Quick Ratio
20.56
Current Ratio
21.73
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.88
EPS next Y
-
EPS next Q
-
EPS this Y
-73.25%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
14.29%
-
-
-
-
SMA20
22.71%
SMA50
72.38%
SMA100
129.11%
Inst Own
-
Inst Trans
-
ROA
-92%
ROE
-101%
ROC
-0.98%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.07-2.95
52W High
+84.5%
52W Low
+269%
RSI
59.51
Rel Volume
16.02
Avg Volume
75.82K
Volume
1.22M
Perf Week
-7.52%
Perf Month
29.47%
Perf Quarter
-10%
Perf Half Y
-13.18%
-
-
-
-
Beta
0.929
-
-
Volatility
0.11%, 0.38%
Prev Close
1.37%
Price
3.69
Change
9.5%

Something similar

Top by Market Cap
3V64.DE
V
AMZN
JPM
MIX.JO
Top Correlated ETFs
RETL
DSTL
XRT
IPAY
IBUY
Top Correlated Stocks
NKTX
RKLB
EXPGY
VFC
FISV
Similar Market Cap
SMCP
USAS
PXE
CDTX
6080.HK

Company Profile

Healthcare Biotechnology
  • Volume Average 75.82K
  • Market Capitalization 40.89M
  • Employee 20
  • CEO Dr. David-Alexandre C. Gros M.D., Ph.D.
  • Headquarters Irvine,CA,US
  • IPO Date 2014-09-17
  • Website https://eledon.com

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.